Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study

Not Applicable

Completed

• Conditions: Chronic Obstructive Pulmonary Disease
• Interventions: Drug: bronchodilator response

• Registration Number: NCT00745043
• Lead Sponsor: Waikato Hospital

Brief Summary

Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out. The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients. This study will investigate what happens to the airways of people taking both of these drugs.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05
• Primary Completion: 2007-08
• Study Completion: 2007-08
• Status Verified: 2008-08
• Study First Submitted: 2008-08-29
• Study First Submitted QC: 2008-08-29
• Study First Posted: 2008-09-01
• Last Update Submitted: 2024-07-25
• Last Update Posted: 2024-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Clinical diagnosis of COPD
• > 40 years of age
• > 15 pack year smoking history

Exclusion Criteria

• Contra-indication to beta-blocker use
• Severe COPD FEV1 < 30% or 1 L
• Not responsive the methacholine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
R302	bronchodilator response	Daily placebo capsules
R304	bronchodilator response	Daily propranolol 80mg capsules
Open Label	bronchodilator response	Daily Metoprolol 190mg capsules
R303	bronchodilator response	Daily metoprolol 95mg capsules

Primary Outcome Measures

Name	Time	Method
Incremental Shuttle Walk Test Result after taking beta-blockers	7-10 days
Bronchodilator response to salbutamol after beta-blockers	7-10 days

Trial Locations

Locations (1)

Department of Respiratory Medicine; 🇳🇿 Hamilton, Waikato, New Zealand